In addition, BMS-345541 treatment increased median survival of the mice by > 2 wk compared with the control (Figure 4C, 78 d for the BMS-345541-treated group vs. 58 d for the control-treated group; P < 0.002), suggesting that the inhibition of NFκB by BMS-345541 could inhibit breast tumor growth in vivo presumably by blocking BCSC function. The gene discussed is NFKB1; the disease is breast neoplasm.